Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

Protamine requirements in cardiac surgery: effect of changes in the heparin reference standard.

Taneja R, Berry L, Pappu U, Stitt L, Sayal P, Allen P, Hoogendoorn H, Chan A.

J Cardiothorac Vasc Anesth. 2014 Oct;28(5):1227-32. doi: 10.1053/j.jvca.2014.04.024.

PMID:
25281041
3.

Thrombelastographic method to quantify the contribution of factor XIII to coagulation kinetics.

Nielsen VG, Kirklin JK, Hoogendoorn H, Ellis TC, Holman WL.

Blood Coagul Fibrinolysis. 2007 Mar;18(2):145-50.

PMID:
17287631
4.

Predictive value of persistent versus transient antiphospholipid antibody subtypes for the risk of thrombotic events in pediatric patients with systemic lupus erythematosus.

Male C, Foulon D, Hoogendoorn H, Vegh P, Silverman E, David M, Mitchell L.

Blood. 2005 Dec 15;106(13):4152-8. Epub 2005 Sep 6.

5.

Heritability of plasma concentrations of clotting factors and measures of a prethrombotic state in a protein C-deficient family.

Vossen CY, Hasstedt SJ, Rosendaal FR, Callas PW, Bauer KA, Broze GJ, Hoogendoorn H, Long GL, Scott BT, Bovill EG.

J Thromb Haemost. 2004 Feb;2(2):242-7.

6.

Absence of elevated anti-alpha-synuclein and anti-EBV latent membrane protein antibodies in PD.

Woulfe JM, Duke R, Middeldorp JM, Stevens S, Vervoort M, Hashimoto M, Masliah E, Chan P, Di Monte DA, Langston JW, Petzinger G, Hoogendoorn H, Munoz DG.

Neurology. 2002 May 14;58(9):1435-6. No abstract available.

PMID:
12011302
7.

Monoclonal antibodies against Epstein-Barr virus cross-react with alpha-synuclein in human brain.

Woulfe J, Hoogendoorn H, Tarnopolsky M, Muñoz DG.

Neurology. 2000 Nov 14;55(9):1398-401.

PMID:
11087792
8.

Uptake of heparin cofactor II and antithrombin into the aorta wall after a deendothelializing injury in vivo: comparison with the behaviors of prothrombin and fibrinogen.

Hatton MW, Ross B, Southward SM, Dereske M, Hoogendoorn H, Blajchman MA, Richardson M.

J Lab Clin Med. 1999 Jan;133(1):81-7.

PMID:
10385486
9.

Comparative metabolism and distribution of rabbit heparin cofactor II and rabbit antithrombin in rabbits.

Hatton MW, Hoogendoorn H, Southward SM, Ross B, Blajchman MA.

Am J Physiol. 1997 May;272(5 Pt 1):E824-31.

PMID:
9176182
10.

[Good results of fasciotomy in chronic compartment syndrome of the lower leg].

Verleisdonk EJ, van den Helder CJ, Hoogendoorn HA, van der Werken C.

Ned Tijdschr Geneeskd. 1996 Dec 14;140(50):2513-7. Dutch.

PMID:
9005334
11.

Circulating dermatan sulfate and heparan sulfate/heparin proteoglycans in children undergoing liver transplantation.

Mitchell L, Superina R, Delorme M, Vegh P, Berry L, Hoogendoorn H, Andrew M.

Thromb Haemost. 1995 Sep;74(3):859-63.

PMID:
8571311
14.

Activation of protein C and its distribution between its inhibitors, protein C inhibitor, alpha 1-antitrypsin and alpha 2-macroglobulin, in patients with disseminated intravascular coagulation.

Scully MF, Toh CH, Hoogendoorn H, Manuel RP, Nesheim ME, Solymoss S, Giles AR.

Thromb Haemost. 1993 May 3;69(5):448-53. Erratum in: Thromb Haemost 1993 Aug 2;70(2):377.

PMID:
7686692
15.
16.

Alpha 2-macroglobulin binds and inhibits activated protein C.

Hoogendoorn H, Toh CH, Nesheim ME, Giles AR.

Blood. 1991 Nov 1;78(9):2283-90.

17.

The fibrinolytic potential of the normal primate following the generation of thrombin in vivo.

Giles AR, Nesheim ME, Herring SW, Hoogendoorn H, Stump DC, Heldebrant CM.

Thromb Haemost. 1990 Jun 28;63(3):476-81.

PMID:
2402750
18.
19.

Uptake of oxygen, release and degradation of hydrogen peroxide by Streptococcus mutans NCTC 10449.

van der Hoeven JS, Hoogendoorn H.

Antonie Van Leeuwenhoek. 1990 Feb;57(2):91-5.

PMID:
2321933
20.

In vivo characterization of recombinant factor VIII in a canine model of hemophilia A (factor VIII deficiency).

Giles AR, Tinlin S, Hoogendoorn H, Fournel MA, Ng P, Pancham N.

Blood. 1988 Jul;72(1):335-9.

21.

A reproducible model for the study of factor X kinetics in AA amyloidosis.

Kisilevsky R, Giles A, Rae G, Hoogendoorn H, Brosseau L, Boudreau L, Tan R.

Exp Mol Pathol. 1988 Jun;48(3):419-26.

PMID:
3371463
22.

Type IIB von Willebrand's disease presenting as thrombocytopenia during pregnancy.

Giles AR, Hoogendoorn H, Benford K.

Br J Haematol. 1987 Nov;67(3):349-53.

PMID:
3500738
23.

Treatment of aphthous patients by enhancement of the salivary peroxidase system.

Hoogendoorn H, Piessens JP.

J Oral Pathol. 1987 Sep;16(8):425-7.

PMID:
2826739
24.

Bioresorption of ceramic strontium-85-labeled calcium phosphate implants in dog femora. A pilot study to quantitate bioresorption of ceramic implants of hydroxyapatite and tricalcium orthophosphate in vivo.

Renooij W, Hoogendoorn HA, Visser WJ, Lentferink RH, Schmitz MG, Van Ieperen H, Oldenburg SJ, Janssen WM, Akkermans LM, Wittebol P.

Clin Orthop Relat Res. 1985 Jul-Aug;(197):272-85.

PMID:
4017341
25.

In vivo studies of the role of factor VII in hemostasis.

Giles AR, Tinlin S, Brosseau L, Hoogendoorn H.

Blood. 1985 May;65(5):1197-200.

26.

[The effect of an enzyme-containing toothpaste on the etiology of dental caries and gingivitis in children 10-13 years old].

Groeneveld A, Kalsbeek H, Hoogendoorn H, Piessens JP.

Ned Tijdschr Tandheelkd. 1984 Dec;91(12):530-3. Dutch. No abstract available.

PMID:
6441891
27.

Factor V (Quebec): a bleeding diathesis associated with a qualitative platelet Factor V deficiency.

Tracy PB, Giles AR, Mann KG, Eide LL, Hoogendoorn H, Rivard GE.

J Clin Invest. 1984 Oct;74(4):1221-8.

28.

Long-term study of large ceramic implants (porous hydroxyapatite) in dog femora.

Hoogendoorn HA, Renooij W, Akkermans LM, Visser W, Wittebol P.

Clin Orthop Relat Res. 1984 Jul-Aug;(187):281-8.

PMID:
6744731
29.

The thrombogenicity of prothrombin complex concentrates. IV. The source of coagulant-active phospholipid.

Giles AR, Hoogendoorn H, Tinlin S.

Thromb Res. 1984 Jun 15;34(6):567-72. No abstract available.

PMID:
6740574
30.

Development of factor VIII:C antibodies in dogs with hemophilia A (factor VIII:C deficiency).

Giles AR, Tinlin S, Hoogendoorn H, Greenwood P, Greenwood R.

Blood. 1984 Feb;63(2):451-6.

31.

Stroma free human platelet lysates potentiate the in vivo thrombogenicity of factor Xa by the provision of coagulant-active phospholipid.

Giles AR, Nesheim ME, Hoogendoorn H, Tracy PB, Mann KG.

Br J Haematol. 1982 Jul;51(3):457-68.

PMID:
7104230
32.
33.

The thrombogenicity of prothrombin complex concentrates: III. The relationship of in vivo thrombogenicity to the nature of the starting plasma.

Giles AR, Hoogendoorn H, Blajchman MA.

Thromb Res. 1981 Feb 1;21(3):255-63. No abstract available.

PMID:
7245138
34.

Preparation and partial characterization of human plasma depleted of antithrombin-III by heparin-sepharose affinity chromatography.

Hoogendoorn H, Cerskus A, Ofosu F, Blajchman M, Hirsh J.

Thromb Res. 1980 Oct 1;20(1):77-83. No abstract available.

PMID:
7209874
35.

The thrombogenicity of prothrombin complex concentrates: II. The effect of thrombocytopenia on in vivo thrombogenicity in rabbits.

Giles AR, Hoogendoorn H, Blajchman MA, Hirsh J.

Thromb Res. 1980 Feb 1-15;17(3-4):555-60. No abstract available.

PMID:
7368174
36.

The thrombogenicity of prothrombin complex concentrates: I. The relationship between in vitro characteristics and in vivo thrombogenicity in rabbits.

Giles AR, Johnston M, Hoogendoorn H, Blajchman M, Hirsh J.

Thromb Res. 1980 Feb 1-15;17(3-4):353-66. No abstract available.

PMID:
6768160
37.

The effect of brushing with a toothpaste containing amyloglucosidase and glucose oxidase on dental caries in rats.

Rotgans J, Hoogendoorn H.

Caries Res. 1979;13(3):150-3. No abstract available.

PMID:
376145
38.
39.

[Influence of the activation of the lactoperoxidase system in saliva on the initiation of caries and chronic, recurrent aphthes. I].

Hoogendoorn H, Scholtes W.

Ned Tijdschr Tandheelkd. 1979 Jan;86(1):36-9. Dutch. No abstract available.

PMID:
297829
40.

[Bacterial inhibition system in saliva].

Hoogendoorn H.

Ned Tijdschr Tandheelkd. 1978 Oct;85(10):404-5. Dutch. No abstract available.

PMID:
295429
41.

Hypothiocyanite ion; the inhibitor formed by the system lactoperoxidase-thiocyanate-hydrogen peroxide. I. Identification of the inhibiting compound.

Hoogendoorn H, Piessens JP, Scholtes W, Stoddard LA.

Caries Res. 1977;11(2):77-84. No abstract available.

PMID:
265188
42.

[The significance of saliva in the etiology of caries].

Hoogendoorn H.

Ned Tijdschr Tandheelkd. 1974 Jun;81(6):225-32. Dutch. No abstract available.

PMID:
4528921
45.

Supplemental Content

Loading ...
Support Center